A Randomized Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine With Our Without a PD-1 Blockade Antibody (Nivolumab) for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas
Phase of Trial: Phase I/II
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Tumour cell vaccine-GVAX (Primary) ; Cyclophosphamide; Nivolumab
- Indications Pancreatic cancer
- Focus Pharmacodynamics
- 13 Mar 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 13 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Jun 2018.
- 10 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.